Empirical Technologies Expands Location and Services

Empirical Technologies expands its locations and services with the launch of Empirical Europe, headquartered in Belgium. Johan Van Havermaet and Xavier Deklerck are leading the company’s European presence. Van Havermaet brings a strong background in spine and emerging technologies to the team. Deklerck has built a career in foot, ankle, and trauma products. Empirical Technologies Founder Dawn Lissy said the expansion of the company she founded has been a long-term goal.

“For years, we’ve looked to Europe as a strong and natural extension of our global footprint,” she said. “For 24 years, we’ve worked to meet the needs of clients around the world. Adding Johan and Xavier to the team means we now have the right professionals in place to better serve a critical segment of the market and our industry in the European Union.” In addition to mechanical testing and Medical Device Directive to Medical Device Regulation support, the Empirical Europe team will provide regulatory support for future MDR and FDA submissions.

The Empirical Technologies engineering team has over 50 years of combined testing experience, participates actively in several ASTM committees, and has hosted FDA reviewers for Experiential Learning Program events. Empirical Technologies’ consulting experts have a proven record of regulatory success with three Breakthrough Device Designations, more than 250 FDA 510(k) clearances, and has recently added a former director of multiple FDA divisions to our panel of experts. To continue providing our clients with top-of-the-line service, our office in the United States will work closely with our office in Belgium.

The Empirical Technologies and Empirical Europe teams are ready to assist clients with their testing and regulatory needs around so they can more quickly navigate regulatory process and get devices to market quickly and efficiently. For more information, visit EmpiricalEurope.com.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version